Susquehanna International Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-41,412
| Closed | -$23.6K | – | 13611 |
|
|
2023
Q4 | $23.6K | Buy |
+41,412
| New | +$25.4K | ﹤0.01% | 11938 |
|
|
2023
Q3 | – | Sell |
-16,793
| Closed | -$23.7K | – | 13200 |
|
|
2023
Q2 | $23.7K | Buy |
+16,793
| New | +$24K | ﹤0.01% | 11595 |
|
|
2022
Q1 | – | Sell |
-29,358
| Closed | -$88.4K | – | 14171 |
|
|
2021
Q4 | $107K | Buy |
+29,358
| New | +$157K | ﹤0.01% | 12103 |
|
|
2021
Q3 | – | Sell |
-14,503
| Closed | -$143K | – | 13749 |
|
|
2021
Q2 | $164K | Sell |
14,503
-27,008
| -65% | -$271K | ﹤0.01% | 11792 |
|
|
2021
Q1 | $384K | Buy |
+41,511
| New | +$433K | ﹤0.01% | 10077 |
|
|
2020
Q3 | – | Sell |
-844
| Closed | -$7.37K | – | 11276 |
|
|
2020
Q2 | $8K | Buy |
844
+169
| +25% | +$2.55K | ﹤0.01% | 9991 |
|
|
2020
Q1 | $10K | Sell |
675
-728
| -52% | -$15.8K | ﹤0.01% | 10049 |
|
|
2019
Q4 | $17K | Sell |
1,403
-684
| -33% | -$11.5K | ﹤0.01% | 9506 |
|
|
2019
Q3 | $53K | Buy |
2,087
+1,048
| +101% | +$30.2K | ﹤0.01% | 9762 |
|
|
2019
Q2 | $26K | Sell |
1,039
-1,109
| -52% | -$42.9K | ﹤0.01% | 9972 |
|
|
2019
Q1 | $91K | Buy |
+2,148
| New | +$48.7K | ﹤0.01% | 8286 |
|
|
2018
Q4 | – | Sell |
-2,487
| Closed | -$102K | – | 10155 |
|
|
2018
Q3 | $174K | Buy |
2,487
+1,697
| +215% | +$129K | ﹤0.01% | 8324 |
|
|
2018
Q2 | $59K | Sell |
790
-3,069
| -80% | -$273K | ﹤0.01% | 9228 |
|
|
2018
Q1 | $367K | Buy |
+3,859
| New | +$662K | ﹤0.01% | 7262 |
|
|
2016
Q4 | – | Sell |
-498
| Closed | -$69.3K | – | 10283 |
|
|
2016
Q3 | $76K | Sell |
498
-35
| -7% | -$4.94K | ﹤0.01% | 8031 |
|
|
2016
Q2 | $61K | Sell |
533
-287
| -35% | -$31.8K | ﹤0.01% | 8197 |
|
|
2016
Q1 | $93K | Buy |
820
+260
| +46% | +$39.4K | ﹤0.01% | 8464 |
|
|
2015
Q4 | $105K | Sell |
560
-1,461
| -72% | -$273K | ﹤0.01% | 8860 |
|
|
2015
Q3 | $344K | Buy |
2,021
+1,050
| +108% | +$379K | ﹤0.01% | 7806 |
|
|
2015
Q2 | $613K | Sell |
971
-2,373
| -71% | -$1.26M | ﹤0.01% | 7227 |
|
|
2015
Q1 | $1.72M | Buy |
3,344
+2,743
| +456% | +$1.38M | ﹤0.01% | 4597 |
|
|
2014
Q4 | $322K | Buy |
+601
| New | +$271K | ﹤0.01% | 8011 |
|
|
2014
Q3 | – | Sell |
-58
| Closed | -$84K | – | 10038 |
|
|
2014
Q2 | $79K | Buy |
+58
| New | +$67.3K | ﹤0.01% | 9496 |
|
|
2014
Q1 | – | Sell |
-198
| Closed | -$230K | – | 9532 |
|
|
2013
Q4 | $197K | Buy |
+198
| New | +$205K | ﹤0.01% | 8288 |
|
|
2013
Q3 | – | Sell |
-50
| Closed | -$55K | – | 8853 |
|
|
2013
Q2 | $55K | Buy |
+50
| New | +$55.7K | ﹤0.01% | 7957 |
|
Other funds holding VIRX
BI
SB
LCM
MCM
ACM
Susquehanna International Group's VIRX Position: Q1 2024 in Review
Susquehanna International Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2024, closing a stake of 41,412 shares — an estimated $23.6K sold.
Susquehanna International Group first reported a position in VIRX in Q2 2013 and held it in 25 quarters. The position peaked at $1.72M in Q1 2015. 40 funds tracked by Wall St. Rank hold VIRX as of Q1 2024.
- Susquehanna International Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Susquehanna International Group sold 41,412 Viracta Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $23.6K.
- Susquehanna International Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 25 quarters.
- Susquehanna International Group's Viracta Therapeutics, Inc. Common Stock position peaked at $1.72M in Q1 2015.
- 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.